Actinium Pharmaceuticals, Inc.

#EHA2024 recap: Abstract detailing the first ever preclinical data from the combination of menin inhibitors with Actinium's ARC Actimab-A in acute myeloid leukemia (AML) models. Results available here: https://bit.ly/3VJRDLX

#EHA2024 presentation recap: median overall survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic #bonemarrowtransplant compared to 1.66 months in patients that did not receive Iomab-B in Phase 3 SIERRA Trial. More details here: https://lnkd.in/gBJF3HT3

Actimab-A is an ARC comprised of a CD33 targeting monoclonal antibody conjugated with the alpha-particle emitter Actinium-225 isotope payload. Read recent data presented at #SNMMI24 as we advance our Actimab program: https://bit.ly/3Ro0ikZ

Actinium recently announced the long-term efficacy results in patients with active relapsed or refractory acute myeloid leukemia also observed in the Phase 3 SIERRA trial. Read more here: https://bit.ly/3VqCTQL #Oncology #EHA2024 #Radiotherapies

Actinium's Proprietary Linker Technology #SNMMI24 presentation recap: Evaluation of novel DOTA-based linkers for improved targeted #radiotherapy delivery to solid tumors. Details: https://bit.ly/3Rpk8vV

Actinium (NYSE: ATNM) Highlights Oral Presentation at #EHA2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial. Read the press release here: https://bit.ly/3VqCTQL #BMT

#SNMMI24 presentation recap: Mathematical Modeling of Exposure Measurements Following High-Dose Targeted Therapy Using 131I-apamistamab: Analysis From the Large Multicenter Phase III SIERRA Trial. Details: https://bit.ly/3Rpk8vV

#SNMMI24 presentation recap: Exploratory Analysis of Bone Marrow Dosimetry from the Randomized Phase 3 SIERRA Trial of Iomab-B Prior to HCT in R/R Acute Myeloid Leukemia. Details: https://bit.ly/3Rpk8vV

Today kicks off #EHA2024. Actinium is looking forward to presenting results from the Phase 3 SIERRA trial of Iomab-B this weekend that showed long-term efficacy results in older patients receiving an Iomab-B led #BMT.

#SNMMI24 presentation recap: Survival Outcomes and Dosimetric Analysis of Iomab-B Followed by Allogeneic Hematopoietic Cell Transplant for Patients with TP53 Mutated R/R #AML. Details: https://bit.ly/3Rpk8vV